Fujian Wanchen Biotechnology Group Future Growth

Future criteria checks 6/6

Fujian Wanchen Biotechnology Group is forecast to grow earnings and revenue by 85.3% and 32.4% per annum respectively. EPS is expected to grow by 85.8% per annum. Return on equity is forecast to be 33.3% in 3 years.

Key information

85.3%

Earnings growth rate

85.8%

EPS growth rate

Food earnings growth	25.5%
Revenue growth rate	32.4%
Future return on equity	33.3%
Analyst coverage	Low
Last updated	27 Aug 2024

Recent future growth updates

Recent updates

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Aug 04

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Jun 06

Earnings and Revenue Growth Forecasts

SZSE:300972 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	41,449	535	N/A	1,400	1
12/31/2025	38,034	367	N/A	1,441	2
12/31/2024	26,600	159	N/A	917	2
6/30/2024	17,992	-76	1,383	1,590	N/A
3/31/2024	13,362	-129	1,035	1,270	N/A
12/31/2023	9,294	-83	804	1,023	N/A
9/30/2023	5,091	-46	-320	-65	N/A
6/30/2023	2,564	40	-298	30	N/A
3/31/2023	1,194	76	-256	57	N/A
1/1/2023	549	48	-246	70	N/A
9/30/2022	546	82	-66	128	N/A
6/30/2022	471	38	0	89	N/A
3/31/2022	448	25	6	81	N/A
1/1/2022	435	23	57	99	N/A
9/30/2021	371	4	38	87	N/A
6/30/2021	399	33	66	122	N/A
3/31/2021	417	65	111	157	N/A
12/31/2020	450	96	100	156	N/A
9/30/2020	449	101	115	162	N/A
6/30/2020	460	110	133	171	N/A
3/31/2020	483	130	155	198	N/A
12/31/2019	451	92	138	177	N/A
9/30/2019	442	82	N/A	N/A	N/A
6/30/2019	418	74	114	151	N/A
3/31/2019	358	28	N/A	N/A	N/A
1/1/2019	343	35	-23	102	N/A
9/30/2018	298	15	N/A	N/A	N/A
6/30/2018	258	-3	-123	63	N/A
3/31/2018	265	24	N/A	N/A	N/A
1/1/2018	247	16	N/A	57	N/A
9/30/2017	259	31	N/A	N/A	N/A
6/30/2017	267	46	N/A	100	N/A
3/31/2017	254	52	N/A	N/A	N/A
12/31/2016	220	39	N/A	80	N/A
9/30/2016	189	40	N/A	59	N/A
6/30/2016	157	30	N/A	40	N/A
3/31/2016	157	31	N/A	49	N/A
12/31/2015	157	33	N/A	58	N/A
9/30/2015	149	30	N/A	48	N/A
6/30/2015	160	37	N/A	68	N/A
3/31/2015	145	35	N/A	67	N/A
12/31/2014	130	34	N/A	66	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300972 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 300972 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300972 is expected to become profitable in the next 3 years.

Revenue vs Market: 300972's revenue (32.4% per year) is forecast to grow faster than the CN market (13.4% per year).

High Growth Revenue: 300972's revenue (32.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300972's Return on Equity is forecast to be high in 3 years time (33.3%)

Fujian Wanchen Biotechnology Group Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target increased by 11% to CN¥31.66

Price target decreased by 27% to CN¥28.54

Recent updates

Price target increased by 11% to CN¥31.66

Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.38 loss in 2Q 2023)

New minor risk - Share price stability

Now 21% overvalued

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Fujian Wanchen Biotechnology Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Less than half of directors are independent

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024

Price target decreased by 27% to CN¥28.54

New minor risk - Shareholder dilution

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.33 loss per share (vs CN¥0.23 profit in 3Q 2022)

Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments

New major risk - Earnings quality

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.15 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Fujian Wanchen Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.16 in 1Q 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.063 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.18 loss in 2Q 2021)

Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022

Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021

Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.17 (vs CN¥0.84 in FY 2020)

Third quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.20 profit in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.03 loss in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.22 in 1Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies